Independent information. England-wide.Public data. Clear sources.

NCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Registered research study with 5 identifiable England locations. See source dates, location-specific recruitment and the original study record.

Study facts

Conditions recorded
Breast Neoplasms
Lead sponsor
Merck Sharp & Dohme LLC
Study type
Interventional
Overall status
Recruiting · this can differ by location
Age range in the record
18 Years to Not specified
Sex eligibility field
All
Healthy volunteers accepted
No, according to the record
Phase
Phase3
Study record last updated
3 September 2026
Study team last verified status
2026-09

These fields are a starting point. Eligibility can include diagnosis, treatment history and other criteria shown only in the complete source record. A registry entry does not establish treatment effectiveness.

England study locations

A location is reproduced as named in the study record. A source map point can represent a town; it is not used here as a hospital entrance or to identify a care provider.

Location in the sourceLocal recruitment statusGeographic connection
The Royal Cornwall Hospital ( Site 1943)

Truro · TR1 3LJ

RecruitingCare in Cornwall

England postcode

St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1940)

London · EC1A 7BE

RecruitingCare in City of London

England postcode

University College London Hospital-Cancer Clinical Trials Unit ( Site 1942)

London · NW1 2PG

RecruitingCare in Camden

England postcode

Blackpool Victoria Hospital ( Site 1941)

Blackpool · FY3 8NR

RecruitingCare in Blackpool

England postcode

City Hospital, Nottingham University Hospitals NHS Trust ( Site 1945)

Nottingham · NG5 1PB

RecruitingCare in Nottingham

England postcode

Questions for the research team

  • Is this exact location currently enrolling participants, and do my circumstances meet the full criteria?
  • What visits, tests, possible risks and follow-up would participation involve?
  • Are travel costs or accessibility arrangements available?
  • How would participation affect my usual care, and what happens if I withdraw?

Source: ClinicalTrials.gov, a United States Government database. Contains OS data © Crown copyright and database right 2026. Contains National Statistics data © Crown copyright and database right 2024; ONS country boundaries (December 2024).

Source processed: 2026-09-10 09:00:04 UTC. Retrieved: 10 September 2026. ClinicalTrials.gov terms.

How we selected and connected these records

Selected registered studies with an overall status of Recruiting or Not yet recruiting and at least one England location established by postcode, recorded nation, or source coordinates within the ONS December 2024 boundary. Retained structured fields; omitted descriptions, eligibility text, contacts and non-England locations. Deduplicated identical locations. Linked local care areas only by exact postcode geography. Location points are used for nation filtering, not directions or facility matching.